Thymidine Metabolism as Confounding Factor of 3'-Deoxy-3'-[18F]Fluorothymidine Uptake after Therapy in a Colorectal Cancer Model.
Fricke, Inga B
Schäfers, Klaus Peter
Aboagye, Eric Ofori
Jacobs, Andreas Hans
Journal of Nuclear Medicine
MetadataShow full item record
Schelhaas, S., Wachsmuth, L., Hermann, S., Rieder, N., Heller, A., Heinzmann, K., Honess, D., et al. (2018). Thymidine Metabolism as Confounding Factor of 3'-Deoxy-3'-[18F]Fluorothymidine Uptake after Therapy in a Colorectal Cancer Model.. Journal of Nuclear Medicine, 59 (7), 1063-1069. https://doi.org/10.2967/jnumed.117.206250
Non-invasive monitoring of tumor therapy response helps in developing personalized treatment strategies. Here, we performed sequential positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging (DW-MRI) to evaluate changes induced by a FOLFOX-like combination chemotherapy in colorectal cancer (CRC) xenografts, to identify the cellular and molecular determinants of these imaging biomarkers. Methods: Tumor bearing CD1 nude mice, engrafted with FOLFOX-sensitive Colo205 CRC xenografts, were treated with FOLFOX (5 fluorouracil, leucovorin and oxaliplatin) in weekly intervals. On d1, d2, d6, d9 and d13 of therapy, tumors were assessed by in vivo imaging and ex vivo analyses. In addition, HCT116 xenografts, which did not respond to the FOLFOX treatment, were imaged on d1 of therapy. Results: In Colo205 xenografts, FOLFOX induced a profound increase in uptake of the proliferation PET tracer 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), which was accompanied by increases in markers for proliferation (Ki67, TK1) and for activated DNA damage response (DDR; γH2AX), whereas the effect on cell death was minimal. As tracer uptake was unaltered in the HCT116 model, these changes appear to be specific for tumor response. Conclusion: We demonstrate that [18F]FLT PET can non-invasively monitor molecular alterations induced by a cancer treatment, including thymidine metabolism and DDR. The cellular or imaging changes may not, however, be directly related to therapy response as assessed by volumetric measurements.
Animal Imaging, DW-MRI, Oncology: GI, PET, [<sup>18</sup>F]FLT, combination cancer therapy, small animal imaging
European Commission FP7 Collaborative projects (CP) (unknown)
Embargo Lift Date
External DOI: https://doi.org/10.2967/jnumed.117.206250
This record's URL: https://www.repository.cam.ac.uk/handle/1810/276841